These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 1601998)

  • 21. The effect of 30 months of low-dose replacement therapy with recombinant human growth hormone (rhGH) on insulin and C-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults.
    Rosenfalck AM; Maghsoudi S; Fisker S; Jørgensen JO; Christiansen JS; Hilsted J; Vølund AA; Madsbad S
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4173-81. PubMed ID: 11095450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus.
    Pennisi P; Gavrilova O; Setser-Portas J; Jou W; Santopietro S; Clemmons D; Yakar S; LeRoith D
    Endocrinology; 2006 Jun; 147(6):2619-30. PubMed ID: 16513827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Leptin is suppressed during infusion of recombinant human insulin-like growth factor I (rhIGF I) in normal rats.
    Böni-Schnetzler M; Hauri C; Zapf J
    Diabetologia; 1999 Feb; 42(2):160-6. PubMed ID: 10064095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of growth hormone and IGF-I on glucocorticoid-induced protein catabolism in humans.
    Oehri M; Ninnis R; Girard J; Frey FJ; Keller U
    Am J Physiol; 1996 Apr; 270(4 Pt 1):E552-8. PubMed ID: 8928758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes.
    Moses AC; Young SC; Morrow LA; O'Brien M; Clemmons DR
    Diabetes; 1996 Jan; 45(1):91-100. PubMed ID: 8522066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin-like growth factor I (rhIGF-I) as a therapeutic agent for hyperinsulinemic insulin-resistant diabetes mellitus.
    Moses AC; Morrow LA; O'Brien M; Moller DE; Flier JS
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S185-94. PubMed ID: 8529513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impaired metabolic response to recombinant insulin-like growth factor-1 in dialysis patients.
    Fouque D; Peng SC; Kopple JD
    Kidney Int; 1995 Mar; 47(3):876-83. PubMed ID: 7752587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recovery of growth hormone release from suppression by exogenous insulin-like growth factor I (IGF-I): evidence for a suppressive action of free rather than bound IGF-I.
    Chapman IM; Hartman ML; Pieper KS; Skiles EH; Pezzoli SS; Hintz RL; Thorner MO
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2836-42. PubMed ID: 9709956
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes.
    Saukkonen T; Amin R; Williams RM; Fox C; Yuen KC; White MA; Umpleby AM; Acerini CL; Dunger DB
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4634-41. PubMed ID: 15356074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults.
    Boulware SD; Tamborlane WV; Rennert NJ; Gesundheit N; Sherwin RS
    J Clin Invest; 1994 Mar; 93(3):1131-9. PubMed ID: 8132753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans.
    Gianotti L; Maccario M; Lanfranco F; Ramunni J; Di Vito L; Grottoli S; Muller EE; Ghigo E; Arvat E
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3604-8. PubMed ID: 11061509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of acute elevation of IGF-I on circulating GH, TSH, insulin, IGF-II and IGFBP-3 levels in non-endocrine short stature (NESS).
    Hanew K; Tanaka A
    J Endocrinol Invest; 2001 Jan; 24(1):1-7. PubMed ID: 11227726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins, and glycemic response in humans.
    Lieberman SA; Bukar J; Chen SA; Celniker AC; Compton PG; Cook J; Albu J; Perlman AJ; Hoffman AR
    J Clin Endocrinol Metab; 1992 Jul; 75(1):30-6. PubMed ID: 1377706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of subcutaneous insulin-like growth factor-I infusion in insulin-dependent diabetes mellitus.
    Bach MA; Chin E; Bondy CA
    J Clin Endocrinol Metab; 1994 Oct; 79(4):1040-5. PubMed ID: 7525624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of recombinant human IGF-I on glucose and leucine kinetics in men.
    Elahi D; McAloon-Dyke M; Fukagawa NK; Sclater AL; Wong GA; Shannon RP; Minaker KL; Miles JM; Rubenstein AH; Vandepol CJ
    Am J Physiol; 1993 Dec; 265(6 Pt 1):E831-8. PubMed ID: 8279537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant human insulin-like growth factor-I enhances whole body protein anabolism and significantly diminishes the protein catabolic effects of prednisone in humans without a diabetogenic effect.
    Mauras N; Beaufrere B
    J Clin Endocrinol Metab; 1995 Mar; 80(3):869-74. PubMed ID: 7533772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term administration of a combination of recombinant growth hormone and insulin-like growth factor-I induces anabolism in maintenance hemodialysis.
    Guebre-Egziabher F; Juillard L; Boirie Y; Laville M; Beaufrère B; Fouque D
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2299-305. PubMed ID: 19401377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome.
    Camacho-Hübner C; Rose S; Preece MA; Sleevi M; Storr HL; Miraki-Moud F; Minuto F; Frystyk J; Rogol A; Allan G; Sommer A; Savage MO
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1246-53. PubMed ID: 16403822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of recombinant human insulin-like growth factor I administration on spontaneous and growth hormone (GH)-releasing hormone-stimulated GH secretion in anorexia nervosa.
    Gianotti L; Pincelli AI; Scacchi M; Rolla M; Bellitti D; Arvat E; Lanfranco F; Torsello A; Ghigo E; Cavagnini F; Müller EE
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2805-9. PubMed ID: 10946886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant human insulin-like growth factor I, recombinant human growth hormone, and sex steroids: effects on markers of bone turnover in humans.
    Mauras N; Doi SQ; Shapiro JR
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2222-6. PubMed ID: 8964855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.